Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.
- MRI Liver Fibrosis device in late-stage clinical validation
- No FY26 revenue expected from fibrosis device, early trial use planned
- Profitable SaaMD platform with 400+ active MRI sites globally
- Strong FY26 guidance: $16M revenue, 14% EBITDA margin
- Device targets $40B liver diagnostics market amid GLP-1 and MASH trial demand
Late-Stage Clinical Validation Targets Biopsy Alternative
Resonance Health (ASX:RHT) is pushing forward with its MRI Liver Fibrosis device, a non-invasive biomarker designed to rival the invasive liver biopsy gold standard. The device is currently in the analysis phase of the DEVIMLA clinical study, having completed patient recruitment with 68 participants verified or scheduled for biopsy. This study aims to validate the device’s diagnostic accuracy and inflammation detection capabilities, positioning it for FDA biomarker qualification and a future commercial launch targeted for FY27/28.
Profitable Platform Fuels Device Development and Market Reach
While the fibrosis device itself is not expected to contribute revenue in FY26, Resonance Health’s existing Software-as-Medical-Device (SaMD) business and clinical trial services underpin a profitable operation. The company guides to $16 million in revenue and a 14% EBITDA margin for FY26, reflecting a 44% year-on-year revenue increase and operational leverage. Resonance’s SaaMD platform already supports over 400 active MRI clinical sites across 48 countries, serving blue-chip pharma clients such as AstraZeneca, GSK, and Pfizer, and offering regulatory cleared products like FerriScan and HepaFatScan.
Addressing a $40 Billion Market Amid Therapeutic Tailwinds
The liver diagnostics market is estimated at over $40 billion globally, with non-invasive imaging fibrosis assessment representing an $8–12 billion segment growing at approximately 8% CAGR. Resonance’s device is positioned to capture demand driven by the recent approvals of MASH therapeutics like Resmetirom and semaglutide, alongside a surge in GLP-1 clinical trials requiring accurate, non-invasive liver fibrosis endpoints. The device leverages standard MRI hardware without contrast agents or special equipment, delivering biopsy-grade accuracy through proprietary analytics that neutralise confounding factors such as iron, fat, and body size.
Competitive Edge in Non-Invasive Liver Fibrosis Assessment
Resonance Health’s approach distinguishes itself from existing modalities like blood biomarkers, FibroScan elastography, and MRI elastography by combining vendor-agnostic MRI sequences with advanced AI-driven analytics designed to overcome limitations such as sampling error and confounders. This positions the device as a scalable, repeatable alternative suitable for population screening and longitudinal monitoring, addressing a critical unmet need in liver disease management and clinical trial recruitment.
Development Roadmap and Upside Potential
The company’s development roadmap outlines clear milestones including multi-site clinical validation, expanded patient cohorts, and regulatory submissions through FDA’s CDER Biomarker Qualification and 510(k) pathways. Early investigational use in pharma-sponsored clinical trials is expected to generate initial revenue and support validation efforts, representing upside beyond FY26 guidance. Resonance also highlights additional portfolio endpoints such as visceral and subcutaneous fat quantification and muscle quality assessment, aligning with evolving regulatory expectations in obesity and metabolic trials.
Bottom Line?
Resonance Health’s MRI Liver Fibrosis device is poised to disrupt liver diagnostics with a highly scalable, non-invasive solution, but commercial returns hinge on upcoming FDA qualification and market adoption beyond FY26.
Questions in the middle?
- How will FDA biomarker qualification timing impact Resonance’s commercial launch?
- What uptake can be expected from pharma trials using the device in investigational settings?
- How will Resonance’s device compete against established non-invasive modalities in real-world clinical practice?